This trial is looking at the use of prostatic artery embolization (PAE) to treat the symptoms of benign prostatic hyperplasia (BPH) in men. The main outcome to be measured is a change in prostate symptoms at 3, 12, 24 and 36 months.
Benign prostatic hyperplasia (BPH) is a non-cancerous growth of the prostate gland. An enlarged prostate can affect bladder function and have a negative impact on quality of life. Treatments for BPH may include medication or surgery to remove excess prostate tissue. Medications for BPH often result in many side effects. BPH surgeries can also lead to complications. PAE involves blocking off some blood vessels which are causing the prostate to grow. Blocking these blood vessels causes the cells to die and the tissue to shrink.
This trial is evaluating the safety and effectiveness of PAE to treat the symptoms of BPH. The main outcome to be measured is the change in prostate symptoms at 3, 12, 24 and 36 months after PAE.
Who are they looking for?
1000 patients will be included in this trial. To be included in this study, patients must be able to give informed consent for any treatment.
Patients cannot be included in the study if they unable or unwilling to provide follow-up information. They also cannot be undergoing PAE for reasons other than BPH with lower urinary tract symptoms.
How will it work
All patients will receive PAE in this study. Patients will be assessed for prostate symptoms at the beginning of the study, 3 months, 12 months, 24 months and 36 months after the treatment. Patients will be assessed for PAE side effects at the beginning of the study, 3 months, 12 months, 24 months and 36 months. Erectile function will also be assessed.